Google
Trusted Resources: News & Events
Latest announcements and gatherings
Voxelotor for Sickle Cell Disease Wins FDA Nod for Patients as Young as 4
Voxelotor has a novel mechanism of action. The first-in-class therapy regulates the affinity of hemoglobin for oxygen, resulting in a decrease in the concentration of deoxygenated sickle hemoglobin (HbS), which forms polymers. It’s hypothesized that because oxygenated HbS cannot polymerize, modifying HbS to increase the proportion of oxygenated to deoxygenated HbS in red blood cells would alter disease severity.
The FDA Friday approved the wider use of voxelotor (Oxbryta) in patients with sickle cell disease (SCD) as young as 4 years of age. In 2019, the oral polymerization inhibitor was approved by the FDA for adults and pediatric patients with SCD 12 years of age and older.
+myBinderRelated Content
-
Emergency Room 101 (tips for the empowered patient)Millions of people find themselves in a ...
-
Assessment of executive functions in preschool children with sickle cell anemiaObjectives: Children with sickle cell a...
-
Petition: Implement NIH Guidelines in Hospital Emergency Rooms when Managing a Sickle Cell CrisisHELP US REACH 1,500 E-SIGNATURES BY DECE...
-
The Life, Death, and Dream of a Research Diversity Crusader“We want to have a nation in which the...
-
Lifespan Comprehensive Sickle Cell CenterThe Lifespan Comprehensive Sickle Cell C...
-
Deepa G. Manwani, MDDr. Manwani completed her residency (199...
-
Williams excels on soccer field while playing with sickle cell traitWomen’s soccer sophomore midfielder Al...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.